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Abstract
Viruses may interfere with the MHC class I antigen presentation pathway in
order to avoid CD8+ T cell-mediated immunity. A key target within this
pathway is the peptide transporter TAP. This transporter plays a central role in
MHC class I-mediated peptide presentation of endogenous antigens. In
addition, TAP plays a role in antigen cross-presentation of exogenously derived
antigens by dendritic cells (DCs). In this study, a soluble form of the cowpox
virus TAP inhibitor CPXV012 is synthesized for exogenous delivery into the
antigen cross-presentation route of human monocyte-derived (mo)DCs. We
show that soluble CPXV012 localizes to TAP+ compartments that carry
internalized antigen and is a potent inhibitor of antigen cross-presentation.
CPXV012 stimulates the prolonged deposition of antigen fragments in storage
compartments of moDCs, as a result of reduced endosomal acidification and
reduced antigen proteolysis when soluble CPXV012 is present. Thus, a dual
function can be proposed for CPXV012: inhibition of TAP-mediated peptide
transport and inhibition of endosomal antigen degradation. We propose this
second function for soluble CPXV012 can serve to interfere with antigen cross-
presentation in a peptide transport-independent manner.
INTRODUCTION
Cytotoxic CD8+ T lymphocytes (CTLs) are vital for the
defense against cancerous or virus-infected cells. CTLs
mount an immune response upon recognition of
antigenic peptides presented by MHC class I (MHC I)
molecules on the surface of target cells. In most cells, the
peptides presented by MHC I are derived from
proteasomal degradation of cytosolic proteins. The
generated peptides are subsequently transported into the
ER by the transporter associated with antigen processing
(TAP). TAP and other proteins of the MHC I peptide-
loading complex ensure proper loading of peptides into
the peptide-binding groove of MHC I molecules. Upon
successful peptide loading, MHC I travels from the ER to
the cell surface, where it displays its peptide cargo to
CD8+ T cells.
Besides its prominent role in presentation of antigens
derived from intracellular proteins, MHC I can also
function in presentation of exogenous antigens in certain
cell types. This process, called antigen cross-presentation,
plays an important role in the activation of naive CD8+ T
cells by antigen presenting cells (APCs), most notably by
dendritic cells (DCs).1-3 Cross-presentation requires
phagocytosis of extracellular antigen and subsequent
endosomal processing.4 In addition, proteins typically
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involved in endogenous MHC I antigen presentation may
also play a role in cross-presentation, including the
proteasome and TAP.4-9
Upon exogenous antigen uptake by DCs, two main
pathways are involved in MHC I antigen cross-
presentation (reviewed in 10-14). A TAP-independent
vacuolar pathway requires lysosomal acidification and
subsequent antigen degradation by endolysosomal
proteases. The generated peptides are directly loaded onto
MHC I molecules in endo-lysosomal compartments.15-21
A second, TAP-dependent, cross-presentation pathway
involves the translocation of phagocytosed cargo into the
cytosol. There, the proteins are degraded into peptides by
the proteasome. These peptides are translocated by TAP
into the ER lumen for access to the endogenous MHC I
loading route. Alternatively, peptides may be re-imported
into the endo-lysosomal compartment by endosomal
TAP6-8 for access to recycling MHC I molecules.9,22,23
Human dendritic cells generally depend on both TAP-
dependent and independent pathways for antigen cross-
presentation.4,24-26 The preferred pathway for cross-
presentation may vary depending on the nature and size
of the internalized antigen.
Various viruses have developed proteins to tackle critical
nodes in the MHC I presentation pathway, including TAP.
Through TAP inhibition, viruses interfere with MHC I
presentation of viral peptides, thereby avoiding T-cell
immunity.27-33 To date, viral TAP inhibitors are found in
herpesviruses, including herpes simplex virus,
varicelloviruses, human cytomegalovirus and Epstein–Barr
virus,34 and several cowpox virus (CPXV) strains.33,35,36 By
blocking TAP, these viral inhibitors deprive MHC I
molecules from antigenic peptides and interfere with the
subsequent induction of a robust CTL response.
Recently, the mechanism of action of the cowpox
virus-derived TAP inhibitor CPXV012 was elucidated.36,37
CPXV012 is a type II transmembrane protein that
localizes to the ER. Here, it directly binds to TAP and
blocks peptide transport by steric interference with ATP
binding. The ER-luminal domain of CPXV012 is
necessary and sufficient for this inhibitory effect.36
Here, we made use of the luminal active domain of
CPXV012 (soluble CPXV012; sCPXV012) outside the
physiological context of CPXV infection and tested it
effects during exogenous delivery into endosomes of
human DCs. We found sCPXV012 to inhibit antigen cross-
presentation without affecting antigen uptake or MHC I
surface display. Soluble CPXV012 is internalized into
TAP+LAMP1+ compartments that also include internalized
antigen. Surprisingly, sCPXV012 blocks endosomal
acidification, which results in antigen preservation and
thus, reduced production of antigenic peptides for MHC I
presentation. We identified the soluble CPXV012 protein,
previously characterized as a potent inhibitor of TAP, to
inhibit antigen cross-presentation in DCs through a
second, TAP-independent mechanism. To our knowledge,
this is the first protein-based compound to interfere with
endosomal acidification.
RESULTS
Soluble CPXV012 inhibits antigen cross-presentation
The cowpox virus protein CPXV012 interferes with the
MHC I antigen presentation pathway by blocking TAP in
the ER.33,35-37 The TAP-inhibiting domain of CPXV012 is
located in the ER-luminal 35 amino acid residues of
CPXV012.36 Endogenous expression of the active domain of
CPXV012 is sufficient for TAP inhibition and preventing
MHC I antigen presentation at the cell surface.36 To
evaluate the ability of the CPXV012 active domain to
interfere with cross-presentation of exogenous antigen by
dendritic cells, a synthetic peptide comprising amino acid
residues 35–69 of full length CPXV012, sCPXV012, was
prepared. The inhibitory capacity of sCPXV012 was tested
in a cross-presentation assay using human monocyte-
derived dendritic cells (moDCs). In this assay, moDCs are
incubated with the viral antigen pp65. This results in
endocytosis and processing of pp65, and MHC I-mediated
presentation of pp65-derived peptides.4 We have shown
previously that pp65 cross-presentation can occur through
both the cytosolic and the vacuolar pathway.4 MHC
I-mediated cross-presentation of pp65-derived peptides was
measured using MHC I-restricted pp65-specific CTLs.
Activation of the CTLs upon cognate interaction was
evaluated by measuring LAMP1 (CD107a) surface
expression and intracellular IFNc and TNF cytokine
production (Figure 1). The addition of sCPXV012 reduced
antigen cross-presentation in a concentration-dependent
manner. At the highest concentration of sCPXV012
(20 lmol L1), cytokine production and LAMP1 expression
by CTLs was reduced by 70–80% (Figure 1). At lower
concentrations of sCPXV012, cytokine production and
LAMP1 expression by CTLS was reduced to 50–60% (using
10 lmol L1 sCPXV012) or 35–40% (using 5 lmol L1
sCPXV012). As negative controls, we included DMSO only
or an irrelevant peptide, both showing no effect on antigen
cross-presentation by moDCs (Figure 1b). sCPXV012 did
not change general MHC I surface expression levels
(Supplementary figure 1), suggesting that endogenous
peptide presentation is not hampered. Indeed, T-cell
activation through direct presentation of pre-processed
pp65(495–503) peptide remained unchanged in the
presence of sCPXV012 (Figure 1c). These combined results
indicate that exogenous addition of sCPXV012 can inhibit
antigen cross-presentation of pp65 by moDCs.
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Identification of the minimal region in sCPXV012
required for inhibition of cross-presentation
To identify the amino acid residues within the active
domain of sCPXV012 that are crucial for inhibition of
cross-presentation, a series of sCPXV012 peptide variants
were synthesized and tested (Figure 2).
Stretches of five amino acids were replaced by alanine
residues in sCPXV012 (Figure 2a). The viability of moDCs
was not affected when incubated with sCPXV012 peptide
variants (data not shown). The peptides were added to
moDCs in the presence of pp65 antigen, and pp65-specific
CTL activation was measured (Figure 2b). In these
experiments, wild type sCPXV012 reduced cross-
presentation to 80% of the levels of untreated moDCs.
Replacement of the first 5 N-terminal amino acids by
alanine residues (Ala1) increased the inhibitory activity of
sCPXV012 almost two-fold, to approximately 63% of the
Figure 1. Levels of antigen cross-presentation in CPXV012-treated moDCs (n = 5). Human moDCs were cultured, harvested and replated in the
absence of presence of soluble CPXV012 or control peptide. After 2 h, 3 lg pp65 antigen (a and b) or 107 molL1 pre-processed pp65(495-503)
(c) was added to the culture. The next day, pp65-specific CTLs were added to the moDCs in a 1:1 ratio in the presence of Golgi-stop. After 4,5 h,
activation of the CTLs was evaluated by determining intracellular levels of IFNc and TNF, and surface LAMP1 expression by antibody staining.
Expression levels were measured by flow cytometry. Statistical analysis was performed on (b) treated conditions compared to DMSO control using
one-sample t-tests and (c) comparison between treated conditions using the Mann–Whitney U test, P < 0.05 were considered significant.
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levels of untreated moDCs, whereas peptides Ala2-Ala7
showed no inhibition at all. In fact, Ala5 and Ala6 even
increased the amount of activated pp65-specific CTLs
possibly suggesting an increase in antigen cross-
presentation.
In addition to alanine-substituted peptides, we
synthesized peptides that were truncated at the N- or C-
terminus (Figure 2c). Soluble CPXV012 with 5 N-terminal
amino acid residues removed (Δ5N) robustly inhibited
antigen cross-presentation (Figure 2d). Further N-terminal
truncations of sCPXV012 abolished its inhibitory activity.
The C-terminally truncated peptides Δ5C and Δ10C also
inhibited antigen cross-presentation, but removal of 15 or
more C-terminal amino acid residues completely abrogated
the inhibitory activity of sCPXV012.
Previous mutagenesis studies on endogenously
expressed full length CPXV012 indicated that the core 25
amino acid residues in the active domain are crucial for
Figure 2. CPXV012 core domain facilitates inhibition of antigen cross-presentation (n = 4). (a, c and e) Overview of soluble mutant CPXV012
peptides used. In each variant, a stretch of five amino acids is replaced by alanine residues. (b, d and f) Antigen cross-presentation by human
monocyte-derived dendritic cells in the absence or presence of 5 lmol L1 of the indicated CPXV012 peptide variants. Data are shown as % of
DMSO control. Statistical analysis was performed on (b) treated conditions compared to DMSO control using one-sample t-tests and (f)
comparison between treated conditions using the Mann–Whitney U test, P < 0.05 were considered significant.
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TAP inhibition, whereas residues 1–5 and 31–34 are
dispensable.36 In consistent with this study, the results
obtained with the peptide variants indicate that a core
region, represented by amino acid residues 6–30 of
sCPXV012, is essential for its inhibitory function. Therefore,
a smaller CPXV012 peptide was tested, comprising these 25
amino acid residues (Figure 2e). This core peptide showed
superior inhibitory capacity compared to wild type
sCPXV012 as well as the other peptide variants tested
(Figure 2f). Thus, sCPXV012 contains a core domain that
allows for highly effective inhibition of antigen cross-
presentation when delivered to human moDCs exogenously.
Co-localisation of antigen and sCPXV012 in LAMP1+
compartments
Antigens endocytosed by DCs are routed to various
compartments of the endolysosomal pathway. Specific
antigen storage compartments facilitate efficient loading
of MHC I with peptides.6,12,22,38-40 In these LAMP1+ and
TAP+ compartments, antigen is further processed for
cross-presentation by MHC I.
To test whether sCPXV012 is directed to
LAMP1+TAP+ compartments after uptake by moDCs, the
intracellular location of the sCPXV012 core peptide was
visualized in moDCs using confocal microscopy. MoDCs
were exposed to sCPXV012 core peptide for 2 h prior to
incubation with pp65 antigen. After 4 h, cells were
stained for sCPXV012 peptide and either LAMP1, TAP1,
or pp65 (Figure 3). Soluble CPXV012 core peptide was
internalized by dendritic cells and partially colocalized
with LAMP1 and TAP1. In addition, sCPXV012 core
peptide showed strong colocalization with pp65 antigen.
These results indicate that both sCPXV012 core peptide
and pp65 are endocytosed and colocalize in part to the
TAP1+ and LAMP1+ antigen storage compartment.
Not all sCPXV012 variants efficiently inhibited cross-
presentation (see Figure 2). This may result from a lack
of inhibitory activity, or inefficient trafficking to pp65+
antigen storage compartments after uptake of CPXV012
peptide by moDCs. Therefore, colocalization of inhibitory
and non-inhibitory CPXV012 variants and pp65 was
investigated 4 h after incubation with moDCs (Figure 4).
Similar to the uptake of CPXV012 core peptide
(Figure 3), Ala1, Ala5 and the wild type CPXV012 peptide
were endocytosed and colocalized with pp65. Although
Ala5 lost its capacity to inhibit cross-presentation
(Figure 2b), it still traffics to pp65+ intracellular
compartments, and its intracellular location is similar to
that of the peptides still inhibiting cross-presentation.
These results show that the differences in MHC I cross-
presentation inhibition by sCPXV012 are not explained by
differential uptake of the sCPXV012 peptide variants.
Preservation of pp65 protein in the presence of
sCPXV012
Cross-presentation of internalized antigen requires
degradation of the antigen for the release of antigenic
peptides, suitable for loading onto MHC I molecules. To
investigate whether sCPXV012 interferes with the process
of antigen break-down we measured the levels of pp65
antigen in dendritic cells.
Dendritic cells were loaded with sCPXV012 for 2 h after
which pp65 antigen was added for another 4 h. Then, DCs
were harvested and stained intracellularly with anti-pp65
antibodies. WT sCPXV012-treated moDCs contained
higher levels of pp65 antigen compared to DMSO-treated
control cells (Figure 5). Similarly, treatment with Ala1 or
core peptide also showed increased presence of pp65
antigen. In contrast, the non-inhibitory peptide Ala5 failed
to enhance intracellular pp65 antigen levels.
Thus, inhibition of cross-presentation by sCPXV012
coincides with increased intracellular antigen levels,
suggesting a role for sCPXV012 in antigen preservation
within endosomes.
Soluble CPXV012 inhibits antigen degradation by
blocking endosomal acidification
As sCPXV012 causes retention of intracellular antigen in
moDCs, we tested the effects of sCPXV012 on antigen
degradation. To this end, sCPXV012 was added to moDCs
in combination with DQ-BSA, a protein that releases
fluorescence upon degradation within the endosomal
pathway. Four hours after uptake, the fluorescence within
moDCs was measured (Figure 6a). While BSA uptake was
similar between the tested conditions (Figure 6a, right
panel), moDCs incubated with WT sCPXV012 showed less
fluorescence compared to DMSO-treated moDCs when
using protease-sensitive DQ-BSA (Figure 6a, left panel)
indicating blocked protein degradation. Accordingly,
mutant sCPXV012 peptides with superior inhibitory
capacity (Ala1 and core) further inhibited protein
degradation. Furthermore, protein degradation levels
measured in moDCs treated with the non-inhibitory Ala5
peptide was comparable to the levels of the DMSO control.
Endosomal proteolysis is dependent on the activity of
proteases within the endosome and is regulated by the
pH. For optimal proteolysis, an acidic environment is
required established by proton influx into the endosomes,
as mediated by vacuolar ATPase proton pumps.41 Soluble
CPXV012 may thus inhibit protein degradation by
preventing acidification of endosomes. The endosomal
pH was tested by adding sCPXV012 to dendritic cells in
combination with pHRodo-dextran, a compound eliciting
fluorescence in acidic environments (Figure 6b). DMSO-
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treated control DCs showed the highest fluorescence,
indicating normal endosomal acidification. Acidification
was prevented by sCPXV012 peptide, as the fluorescence
measured in these moDCs was significantly decreased.
Similarly, Ala1 and core peptides that inhibited cross-
presentation as well as DQ-BSA proteolysis, also blocked
endosomal acidification. In contrast, Ala5 peptide, which
lacks inhibition of cross-presentation or DQ-BSA
proteolysis indeed shows higher pH-dependent
fluorescence compared to WT sCPXV012. The inability
of antigen cross-presentation in the presence of
sCPXV012 strongly correlated with a decrease in antigen
processing in the presence of sCPXV012, showing a
Spearman rank correlation coefficient of R = 0.833
(Figure 6c).
Altogether, sCPXV012 interferes with the antigen cross-
presentation abilities of moDCs through prevention of
endosomal acidification. This results in antigen preservation
rather than degradation into antigenic peptides.
DISCUSSION
When endogenously expressed, the active domain of
CPXV012 is present in the ER lumen where it limits the
Figure 3. CPXV012 core peptide and pp65 antigen are taken up into TAP+LAMP1+ compartments (n = 3). Confocal images of human moDCs
loaded with CPXV012 core peptide for 2 h, following followed by pp65 internalization for four more hours. DCs were stained for either LAMP1,
TAP1 or pp65. Overlays are shown in the bottom panel. Each column represents a distinct visual field. Bar size: 7.5 lm. TAP, transporter
associated with antigen processing.
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availability of peptides for loading onto class I complexes,
through blockage of the TAP transporter.33,35-37 During
CPXV infection, direct antigen presentation by infected
cells is therefore blocked while antigen cross-presentation
by DCs was not affected.42 In this study, we take the
active domain of CPXV012 outside its physiological
context of CPXV infection and show that it is able to
inhibit antigen cross-presentation when exogenously
delivered to moDCs. Soluble CPXV012 is internalized
into LAMP1+ endosomal compartments that carry TAP
in their membrane. Pp65 antigen is also targeted to these
compartments, where it is processed for cross-
presentation. Unexpectedly, sCPXV012 interferes with the
endosomal processing of antigen by blocking acidification
of the endosome, thereby preventing antigen proteolysis.
Thus, we show a second function for CPXV012, in
interfering with DC antigen cross-presentation in a TAP-
independent manner.
The TAP-independent vacuolar pathway of cross-
presentation includes antigen processing and MHC I
loading within endo-lysosomal compartments. Several
reports indicate that antigen cross-presentation can depend
exclusively on the vacuolar pathway.17-19 Inhibition of
endosomal acidification17,19 or endosomal proteases17,18
abrogated cross-presentation through TAP-independent
pathways. Our study shows that sCPXV012 inhibits
antigen cross-presentation by preventing antigen
degradation. Upon entering the endosomal pathway
through endocytosis, sCPXV012 can block antigen cross-
presentation through interference with pH-dependent
Figure 4. CPXV012 peptide variants localize to endosomal compartments also containing internalized pp65 antigen (n = 3). Confocal images of
human moDCs loaded with CPXV012 peptide variants (2 h) and pp65 antigen (4 h), respectively. Overlays are shown in the bottom panel. Each
column represents a distinct visual field. Bar size: 7.5 lm.
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antigen degradation, separate from its function as TAP
inhibitor.
Our finding that sCPXV012 can target pH-dependent
endosomal antigen degradation is relevant, as for both
TAP-dependent and TAP-independent pathways of
antigen cross-presentation, endosomal proteolysis is
considered crucial.4,16,43-45
In addition, sCPXV012 may directly affect the TAP-
dependent cross-presentation pathway by inhibiting TAP
in the endosome. CPXV012 peptide was shown to act on
the luminal domain of TAP36 which is accessible from
inside the endosome. As CPXV012 peptide localizes to
TAP+ compartments, it is possible that endosomal TAP
is inhibited by CPXV012 peptide. In line with this, the
Figure 5. Antigen preservation in CPXV012-treated moDCs (n = 4). (a) Human moDCs were loaded with the indicated CPXV012 peptide
variants for 2 h, followed by pp65 loading for 4 h. moDCs were harvested, permeabilized and stained with anti-pp65 antibodies. Levels of pp65-
positive moDCs were measured by flow cytometry. Quantification of the data is shown in (b) Statistical analysis was performed on comparison
between treated conditions using the Mann–Whitney U test, P < 0.05 were considered significant.
Figure 6. CPXV012 blocks antigen processing in dendritic cells (n = 5). Human moDCs were loaded with the indicated CPXV012 peptide
variants for 2 h, followed by DQ-BSA (a, left panel), Alexa647-BSA (a, right panel) or pHRodo-dextran (b) loading for 4 h. DCs were harvested
and levels of fluorescence were measured by flow cytometry. c. Cross-presentation data (Figure 2b) and DQ-BSA processing data (Figure 6a, left
panel) of sCPXV012 peptide variants were tested for correlation using Spearman’s rank correlation test. Statistical analysis was performed on
comparison between treated conditions using the Mann–Whitney U test, P < 0.05 were considered significant.
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inhibitory capacity of CPXV012 alanine variants
correlates well with the ability of full-length
endogenously-expressed CPXV012 variants to inhibit
peptide transport by TAP.36 There, TAP inhibition was
observed for full-length variants with an intact core
domain exactly corresponding to those variants that
showed inhibitory activity against cross-presentation in
the study presented here.
Possibly, inhibition of endosomal acidification may
even promote the TAP-dependent antigen-cross
presentation route,46 but such analysis falls beyond the
scope of our manuscript. Our data do however, support
that sCPXV012 might have a dual role by inhibiting both
endosomal acidification and blocking import of antigens
by TAP.
Nevertheless, without excluding a possible role for
sCPXV012 blocking endosomal TAP, the pronounced
inhibition of antigen proteolysis by sCPXV012
observed in this study smothers antigen cross-
presentation directly at initiation. Thereby, sCPXV012
is the first protein-based compound to block
endosomal acidification. Other acidification inhibitors
include lysomotropic agents such as chloroquine,
ammonium chloride or siramesine that broadly block
acidification of the entire endo-lysosomal pathway
within the cell. A protein-based acidification inhibitor
offers the possibility of affecting specific compartments
using targeted delivery by antibody-receptor
engagement or by fusion to ligands. CPXV012 peptide
can thus be used to investigate the role of acidification
in different endosomal uptake routes, including
pathways used by plasma membrane proteins and
intracellular pathogens.
METHODS
Reagents and antibodies
DQ-BSA (Cat. D12050), pHRodo-dextran (Cat. P10361),
Hoechst (Cat. H1399) and TO-PRO3 (T3605) were
purchased from Thermo Fisher Scientific, Waltham, MA,
USA. Antibodies used: anti-HLA-A/B/C (Clone W6/32,
Biolegend, San Diego, CA, USA); anti-CD11c (Clone B-Ly6,
BD Biosciences, Vianen, The Netherlands); anti-CD3 (Clone
UCHT1, Sony Biotechnology, Weybridge, UK); anti-CD8
(Clone RPA-T8, BD Biosciences); anti-LAMP1 (Clone
H4A3, BD Biosciences); anti-TNF (Clone MAB11, Sony
Biotechnology); anti-IFNc (Clone 4S.B3, BD Biosciences);
anti-MHC-I (W6/32, Sony Biotechnology); anti-pp65 mouse
mAb (Advanced Biotechnologies Inc, Eldersburg, MD,
USA); anti-TAP1 (clone 148.3, EMD Millipore); anti-mouse
FITC-conjugated donkey pAb (Jackson ImmunoResearch);
Cy3-conjugated streptavidin (Jackson ImmunoResearch).
CPXV012 peptide synthesis
The sequences of the CPXV012 peptide variants are
indicated in Figure 2. The control peptide is derived
from the ER-luminal domain of pseudorabies virus
TAP inhibitor UL49.5, and comprises amino acid
residues 28–59 of this protein (sequence:
STEGPLPLLREESRINFWNAACAARGVPVDQP). The
ER-luminal domain of UL49.5 is not capable of
inhibiting TAP when expressed in cells47 or when
added as a peptide (Figure 1b). Synthetic peptides
were prepared by normal Fmoc chemistry using
preloaded Tentagel resins, using PyBop/N-
methylmorpholine for in situ activation and 20%
piperidine in N-methylpyrrolidinon for Fmoc
removal.48 Couplings were performed for 75 min.
After final Fmoc removal, peptides were cleaved with
trifluoroacetic acid/H2O 19:1 v/v containing
additional scavengers when C or W residues were
present in the peptide sequence. Peptides were
isolated by ether/pentane precipitation and checked
for purity using reversed-phase UPLC–mass
spectrometry. The integrity was tested using MALDI-
TOF mass spectrometry. Cysteines were replaced by
the isosteric alpha-amino-n-butyric acid. Lyophilized
peptides were dissolved in DMSO. Peptide
concentrations were confirmed by the NanoDrop
spectrophotometer (Thermo Scientific) using the
absorbance of Trp at 280 nm. Peptides were aliquoted
in Eppendorf LoBind microcentrifuge tubes (Sigma-
Aldrich) and kept at 20°C for short-term storage.
Human monocyte-derived DC culture
Peripheral blood mononuclear cells (PBMCs) from
healthy donors were separated from peripheral blood by
ficoll isopaque density gradient centrifugation (GE
Healthcare Bio-Sciences AB). CD14+ monocytes were
isolated by positive selection with CD14 MACS beads
(Miltenyi). CD14+ cells were cultured at a concentration
of 1 9 106 mL1 for 5 days at 37°C and 5% CO2 in X-
VIVO15 medium containing 450 U mL1 GM-CSF
(Immunotools) and 300 U mL1 IL-4 (Immunotools).
Cytokines were refreshed after 3 days. DCs were collected
for experiments on day 5 by incubation in PBS (4°C) for
1 h. Generally, moDCs cultured from at least three
different donors were used for experiments.
Cross-presentation assay
A HCMV pp65–specific CD8+ T-cell clone was
prepared previously.4 In brief, T cells from an HLA-
A*0201+ donor were stained with HLA-A2/pp65495-503
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tetramers, and subsequently single-cell sorted in a 96-
well plate (Thermo) containing irradiated B-LCL feeder
cells (1 9 105 cells mL-1, irradiated with 70 Gy) and
PBMCs from three healthy donors (1 9 106 cells mL-1,
irradiated with 30 Gy). One lg mL1 leucoagglutinin
PHA-L (Sigma-Aldrich) and 120 U mL1 of recombi-
nant IL-2 (Immunotools) were added. T-cell clones
specific to pp65495-503 were selected using tetramer
staining. Positive clones were restimulated and
expanded during several stimulation cycles and frozen
in aliquots that were freshly thawed before each use in
an assay. DCs were loaded with soluble HCMV pp65
protein (Miltenyi Biotec, purity >95%, low endotoxin;
<10 EU mL1) and incubated overnight at 37°C and
5% CO2 for processing. HCMV pp65-specific CD8
+T
cells were cocultured with pp65–loaded DCs for 4–6 h
in the presence of Golgistop (1/1500; BD Bioscience).
Cells were subsequently stained for surface markers and
presence of intracellular IFNc and TNF, followed by
flow cytometry–based analysis.
Flow cytometry
For stainings, cells were first washed twice in PBS
containing 2% FCS (Invitrogen) and 0.1% sodium azide
(NaN3, Sigma-Aldrich). Next, antigen nonspecific binding
was prevented by prior incubation of cells with 10%
mouse serum (Fitzgerald). Cells were incubated with
indicated fluorophore-conjugated mouse anti–human
antibodies for 20 min on ice and washed twice. In case of
intracellular stainings, cells were fixed and permeabilized
(Fix/Perm kit BD Biosciences) after surface staining and
subsequently stained with indicated antibodies for 30 min
on ice and washed twice. Cells were taken up in PBS (2%
FCS/0,1% NaN3) to be used for measurement using
either FACSCanto II or Fortessa with FACS Diva Version
6.13 (BD Bioscience). Analysis was done using FlowJo
Version 10 software.
Confocal microscopy
MoDCs were cultured in a LabTek 8 well chamber
coated with 8GX alcain blue. After 5 days, cells were
incubated with peptide (5 lmol L1) or DMSO as a
vehicle control. After 2 h, pp65 (3 lg mL1) was added
and cells were incubated for 4 h. Cells were subsequently
washed and fixed for 10 min at RT using PBS
supplemented with 4% formaldehyde. Cells were
permeabilized in PBS supplemented with 0.1% Triton
for 10 min at RT, and blocked for 30 min with PBS
supplemented with 5% normal goat serum. Next, slides
were incubated with primary antibodies. Cells were
washed and incubated with secondary antibodies. After
washing, slides mounted on a microscope slide using
Mowiol 4-88 (Carl Roth, Germany). Samples were
imaged using a Leica TCS SP5 confocal microscope
equipped with a HCX PL APO CS 9 63/1.40-0.60 OIL
objective (Leica Microsystems, The Netherlands).
Fluorescent signals were detected with PMTs set at the
appropriate bandwidth using the 488 nm argon laser for
FITC, the 543 helium neon laser for Cy3, and the
633 nm helium neon laser for TO-PRO3. Images were
processed using the Leica SP5 software.
STATISTICS
For statistical testing between two groups non-parametric
Mann–Whitney tests are used. P < 0.05 is considered
significant. All calculations were performed using
GraphPad Prism 6.
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